查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967781

高活性原料藥（ API）契約製造市場－全球產業規模、佔有率、趨勢、機會和預測：按製劑、最終用途、地區和競爭格局分類，2021-2031年

High Potency API Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球高活性原料藥（HPAPI）契約製造市場預計將從 2025 年的 85.2 億美元大幅成長至 2031 年的 142.2 億美元，複合年成長率為 8.91%。

該領域專注於低劑量下即可產生生物效應的藥理活性物質的合約生產。由於癌症發病率上升以及製藥業向標靶癌症療法的轉型，對這種能力的需求日益成長。處理這些複雜的製劑需要先進的生物安全設施和專業技術，而許多藥物研發公司缺乏這些資源，因此越來越依賴具備資格的合約研發生產機構（CDMO）來彌補這一營運缺口。

市場概覽
預測期 2027-2031
市場規模：2025年 85.2億美元
市場規模：2031年 142.2億美元
複合年成長率：2026-2031年 8.91%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

根據歐洲製藥工業協會聯合會（EFPIA）的數據，預計到2024年，歐洲製藥業在研發領域的投資將達到550億歐元。如此龐大的藥物開發平臺投入凸顯了市場對能夠安全處理高活性化合物的專業生產合作夥伴日益成長的需求。然而，該產業的成長受到許多障礙的限制，尤其是實施先進的隔離技術和維持嚴格的監管合規標準以有效防止交叉污染所需的巨額資金。

市場促進因素

全球癌症和慢性疾病負擔日益加重，是推動高活性原料藥（API）契約製造行業成長的主要動力。隨著癌症發生率的上升，製藥研發人員越來越關注低劑量即可發揮療效的高活性分子。由於處理細胞毒性物質本身存在風險和複雜性，這種轉變通常需要採取專門的防護措施，而這些物質的生產也擴大外包。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，預計僅在美國就將新增2,001,140例癌症病例。這項統計數據促使生產商與具備完善的安全通訊協定和工業衛生標準的合約組織合作，以擴大這些關鍵治療方法的生產規模。

同時，抗體藥物複合體（ADC）需求的激增正在重塑製藥業的模式。 ADC透過複雜的結合過程，將抗體的特異性與小分子藥物的效力結合。自行開發生物製藥和化學製劑的生產能力成本高昂，促使生物製藥公司轉向專業的合約組織，以獲得必要的基礎設施，同時避免固定成本的負擔。三星生物製劑在2024年1月發布的新聞稿印證了這一趨勢，新聞稿確認該公司正在其BioCampus II園區內建造一座獨立的ADC生產設施，以滿足客戶需求。此舉與整個產業的擴張趨勢相符，美國FDA在前一年核准的55種新藥就證明了這一點。

市場挑戰

高活性原料藥（HPAPI）契約製造產業的擴張受到阻礙，主要原因是實施先進的隔離技術和遵守嚴格的監管標準需要大量的資本投入。生產高活性化合物需要專門的基礎設施，例如負壓空調系統和堅固的隔離器，以確保工人安全並消除交叉污染的風險。這些設施需要大量的前期投資，並且由於需要維持符合職業暴露限值，營運成本也會增加。這種經濟現實有效地阻止了小規模合約研發生產機構（CDMO）進入市場，從而限制了可用供應商的總數。

這種資本密集結構造成了供給能力瓶頸，儘管對高活性化合物的需求不斷成長，卻阻礙了市場成長。由於能夠承擔必要設備升級的製造商數量有限，該行業極易受到供不應求和營運柔軟性下降的影響。美國化學製造商協會 (SOCMA) 2024 年的數據凸顯了這項投資的緊迫性，數據顯示，95% 的契約製造製造商和委託製造製造商都制定了資本投資計劃以支持新技術和新產品，這凸顯了嚴重的財務負擔，並減緩了新產能的部署。

市場趨勢

在活性原料藥（HPAPI）的契約製造領域，一場向一體化「一站式服務」模式的根本性轉變正在進行中。此模式要求合約研發受託製造廠商（CDMO）整合價值鏈，提供從研發到生產的端到端服務。透過集中處理從分子合成到最終製劑填充和包裝的整個流程，可以降低不同供應商之間高活性化合物轉移帶來的物流風險。這項策略在抗體藥物複合體（ADC）複雜的供應鏈中尤其重要。 2024年9月，Piramal Pharma Solutions宣布投資8,000萬美元擴建位於肯塔基州列剋星敦的工廠，凸顯了整合趨勢。該公司旨在加強其一體化無菌注射劑生產能力，並擴展其全面的「ADCelerate」計畫。

同時，市場正從傳統的腫瘤治療領域拓展，高活性原料藥（HPAPI）的應用範圍正擴展到多種非腫瘤治療領域。為了滿足代謝性疾病（如肥胖症和糖尿病）以及自體免疫疾病對高活性藥物日益成長的需求，製造商正在開發基礎設施以處理包括胜肽在內的各種藥物。為了順應這一趨勢，合約研發生產機構（CDMO）CordenPharma承諾在三年內投資9億歐元，以加速其在歐洲和美國的GLP-1肽生產。 Labiotech.eu於2024年8月報導了這一消息，這表明CordenPharma堅定致力於支持這些不斷擴展的治療領域。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球高蛋白原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 劑型類型（注射劑、口服固態劑型、乳液劑型、其他）
    • 最終用途分類（腫瘤科、抗糖尿病藥物、自體免疫疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美高活性原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲高活性原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區高活性原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲高活性原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美高活性原料藥（HPAPI）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球高活性原料藥（HPAPI）契約製造市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Catalent, Inc.
  • Lonza Group
  • Piramal Pharma Solutions
  • Pfizer CentreOne
  • Gentec Pharmaceutical Group
  • AbbVie Contract Manufacturing
  • Corden Pharma International
  • Curia Global, Inc.
  • SigmaAldrich Co., LLC
  • Polpharma Group

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18843

The Global High Potency API (HPAPI) Contract Manufacturing Market is projected to expand significantly, rising from USD 8.52 billion in 2025 to USD 14.22 billion by 2031, reflecting a CAGR of 8.91%. This sector focuses on the outsourced production of pharmacologically active substances that induce biological effects at minute dosages, a capability increasingly sought after due to the rising incidence of cancer and the pharmaceutical industry's shift toward targeted oncology therapies. Since handling these complex modalities requires specialized high-containment infrastructure and expertise that many innovator firms lack internally, there is a growing necessity to rely on competent contract development and manufacturing organizations to bridge this operational gap.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.52 Billion
Market Size 2031USD 14.22 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentOncology
Largest MarketNorth America

Data from the European Federation of Pharmaceutical Industries and Associations indicates that in 2024, the pharmaceutical industry allocated an estimated €55,000 million to research and development within Europe. This massive investment in the drug development pipeline highlights the escalating need for specialized manufacturing partners capable of safely managing potent compounds. However, the sector's growth is tempered by substantial barriers, specifically the immense capital required to install advanced containment technologies and maintain rigorous regulatory compliance standards to effectively prevent cross-contamination.

Market Driver

The escalating global burden of oncology and chronic diseases serves as the primary engine for growth in the High Potency API contract manufacturing industry. As cancer rates climb, pharmaceutical developers are increasingly focusing on highly potent molecules that achieve greater efficacy at lower doses, a shift that demands specialized containment measures often outsourced due to the inherent risks and complexities of handling cytotoxic materials. According to the American Cancer Society's "Cancer Facts & Figures 2024," released in January 2024, it was estimated that 2,001,140 new cancer cases would be diagnosed in the United States alone, a statistic that compels manufacturers to partner with contract organizations possessing the established safety protocols and industrial hygiene standards necessary for scaling these critical therapies.

Simultaneously, the manufacturing landscape is being redefined by the surging demand for Antibody-Drug Conjugates (ADCs), which merge antibody specificity with small-molecule potency through complex conjugation processes. Because developing internal capabilities for both biologic and chemical manufacturing is prohibitively expensive, biopharmaceutical companies are turning to specialized contract organizations to access required infrastructure without the burden of fixed costs. This trend is exemplified by Samsung Biologics, which confirmed in a January 2024 press release that it was constructing a standalone ADC facility at its Bio Campus II to support client needs, a move that parallels the industry's broader momentum as evidenced by the U.S. FDA's approval of 55 novel drugs in the preceding year.

Market Challenge

The expansion of the HPAPI contract manufacturing sector is significantly hindered by the high capital expenditures required to install advanced containment technologies and adhere to strict regulatory standards. Producing potent compounds demands specialized infrastructure, such as negative-pressure HVAC systems and rigid isolators, to guarantee operator safety and eliminate the risk of cross-contamination. These facilities necessitate heavy upfront investment and result in elevated operational costs to maintain compliance with occupational exposure limits, a financial reality that effectively bars smaller contract development and manufacturing organizations from entering the market and restricts the overall number of capable suppliers.

This capital-intensive dynamic creates capacity bottlenecks that stifle market growth despite increasing demand for potent compounds. With only a limited number of manufacturers able to afford the requisite upgrades, the industry is vulnerable to supply shortages and diminished operational flexibility. The urgency of these investments is highlighted by 2024 data from the Society of Chemical Manufacturers & Affiliates, which noted that 95% of contract and toll manufacturers intended to undertake capital expenditure projects to support new technologies and products, underscoring the severe financial strain that slows the deployment of new manufacturing capacity.

Market Trends

The HPAPI contract manufacturing sector is undergoing a fundamental shift toward integrated "one-stop-shop" service models, where CDMOs consolidate their value chains to provide end-to-end development and manufacturing. By unifying processes ranging from molecule synthesis to final drug product fill-finish, companies can mitigate the logistical risks involved in transferring potent compounds between different vendors, a strategy particularly crucial for the complex supply chains of antibody-drug conjugates (ADCs). This trend toward consolidation was highlighted in September 2024 by Piramal Pharma Solutions, which announced an $80 million investment to expand its Lexington, Kentucky facility, aiming to enhance its integrated sterile injectable capabilities and bolster its comprehensive "ADCelerate" program.

Concurrently, the market is broadening its scope beyond traditional oncology applications as HPAPI utilization diversifies into non-oncology therapeutic areas. Manufacturers are increasingly adapting their production lines to meet the booming demand for high-potency treatments for metabolic disorders, such as obesity and diabetes, as well as autoimmune diseases, necessitating infrastructure capable of handling diverse modalities like peptides. Reflecting this pivot, the CDMO CordenPharma pledged €900 million over three years to accelerate GLP-1 peptide production in Europe and the United States, as reported by Labiotech.eu in August 2024, signaling a major commitment to supporting these expanding therapeutic categories.

Key Market Players

  • Catalent, Inc.
  • Lonza Group
  • Piramal Pharma Solutions
  • Pfizer CentreOne
  • Gentec Pharmaceutical Group
  • AbbVie Contract Manufacturing
  • Corden Pharma International
  • Curia Global, Inc.
  • SigmaAldrich Co., LLC
  • Polpharma Group

Report Scope

In this report, the Global High Potency API (HPAPI) Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

High Potency API (HPAPI) Contract Manufacturing Market, By Formulation

  • Injectables
  • Oral Solids
  • Lotions
  • Others

High Potency API (HPAPI) Contract Manufacturing Market, By End Use

  • Oncology
  • Antidiabetics
  • Autoimmune
  • Others

High Potency API (HPAPI) Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global High Potency API (HPAPI) Contract Manufacturing Market.

Available Customizations:

Global High Potency API (HPAPI) Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Formulation (Injectables, Oral Solids, Lotions, Others)
    • 5.2.2. By End Use (Oncology, Antidiabetics, Autoimmune, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Formulation
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Formulation
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Formulation
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Formulation
        • 6.3.3.2.2. By End Use

7. Europe High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Formulation
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Formulation
        • 7.3.1.2.2. By End Use
    • 7.3.2. France High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Formulation
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Formulation
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Formulation
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Formulation
        • 7.3.5.2.2. By End Use

8. Asia Pacific High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Formulation
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Formulation
        • 8.3.1.2.2. By End Use
    • 8.3.2. India High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Formulation
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Formulation
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Formulation
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Formulation
        • 8.3.5.2.2. By End Use

9. Middle East & Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Formulation
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Formulation
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Formulation
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Formulation
        • 9.3.3.2.2. By End Use

10. South America High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Formulation
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Formulation
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Formulation
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Formulation
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global High Potency API (HPAPI) Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Catalent, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza Group
  • 15.3. Piramal Pharma Solutions
  • 15.4. Pfizer CentreOne
  • 15.5. Gentec Pharmaceutical Group
  • 15.6. AbbVie Contract Manufacturing
  • 15.7. Corden Pharma International
  • 15.8. Curia Global, Inc.
  • 15.9. SigmaAldrich Co., LLC
  • 15.10. Polpharma Group

16. Strategic Recommendations

17. About Us & Disclaimer